Published in Cancer Res on March 09, 2010
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology (2014) 1.85
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene (2014) 1.69
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer (2015) 1.39
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26
miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One (2012) 1.20
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) (2010) 1.19
STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol (2013) 1.19
STAT inhibitors for cancer therapy. J Hematol Oncol (2013) 1.16
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs (2011) 1.03
HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res (2013) 1.00
Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One (2012) 0.99
The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer (2010) 0.98
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene (2013) 0.94
FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. Cell Death Differ (2011) 0.93
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget (2014) 0.93
Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des (2013) 0.93
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer (2011) 0.93
Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev (2012) 0.92
Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene (2015) 0.92
Regulation of STATs by polycystin-1 and their role in polycystic kidney disease. JAKSTAT (2013) 0.91
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res (2015) 0.90
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience (2014) 0.89
Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg (2011) 0.88
Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients (2016) 0.87
LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells. Anticancer Res (2011) 0.86
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models. Oncogenesis (2013) 0.85
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. ACS Med Chem Lett (2010) 0.85
The oncogenic potential of human cytomegalovirus and breast cancer. Front Oncol (2014) 0.85
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Am J Transl Res (2014) 0.84
XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One (2012) 0.84
STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration. Curr Mol Med (2016) 0.83
STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol (2016) 0.82
Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget (2016) 0.82
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther (2014) 0.82
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget (2015) 0.80
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. Cell Rep (2016) 0.80
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. Am J Cancer Res (2015) 0.80
A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget (2016) 0.80
Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol (2016) 0.79
2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorg Med Chem Lett (2014) 0.79
Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. Int J Clin Exp Pathol (2014) 0.79
Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. BMC Cancer (2015) 0.79
Pancreatic cancer chemoprevention by phytochemicals. Cancer Lett (2012) 0.78
MiR-148a Functions as a Tumor Suppressor by Targeting CCK-BR via Inactivating STAT3 and Akt in Human Gastric Cancer. PLoS One (2016) 0.78
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget (2016) 0.78
Profiling CCK-mediated pancreatic growth: the dynamic genetic program and the role of STATs as potential regulators. Physiol Genomics (2011) 0.77
STAT3 Signaling in Polycystic Kidney Disease. Drug Discov Today Dis Mech (2013) 0.77
The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. PLoS One (2013) 0.76
2-Methoxystypandrone inhibits signal transducer and activator of transcription 3 and nuclear factor-κB signaling by inhibiting Janus kinase 2 and IκB kinase. Cancer Sci (2014) 0.76
Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer Prev Res (Phila) (2015) 0.75
Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy. Sci Rep (2017) 0.75
Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget (2016) 0.75
STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Int J Oncol (2016) 0.75
Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology (2017) 0.75
Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan. PLoS One (2014) 0.75
STAT3 Inhibition as a Therapeutic Strategy for Chordoma. J Neurol Surg B Skull Base (2016) 0.75
Prosapogenin A induces apoptosis in human cancer cells in vitro via inhibition of the STAT3 signaling pathway and glycolysis. Oncol Lett (2013) 0.75
Mitochondrial Stat3, the Need for Design Thinking. Int J Biol Sci (2016) 0.75
Cystathionine- γ-lyase promotes process of breast cancer in association with STAT3 signaling pathway. Oncotarget (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Stat3 as an oncogene. Cell (1999) 17.39
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Curcumin: the Indian solid gold. Adv Exp Med Biol (2007) 4.12
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Tracking STAT nuclear traffic. Nat Rev Immunol (2006) 2.99
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood (2002) 2.90
STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett (2006) 2.77
Roles of STAT3 defined by tissue-specific gene targeting. Oncogene (2000) 2.71
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem (1996) 2.39
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene (2002) 2.32
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene (2001) 2.25
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene (2004) 1.96
Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem (2005) 1.62
Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol (1997) 1.51
STAT-1: a novel regulator of apoptosis. Int J Exp Pathol (2003) 1.43
Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem (2006) 1.42
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res (2006) 1.32
Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer (2006) 1.12
Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem (2008) 0.94
Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane. Int J Mol Med (1999) 0.90
Determination of cell colony formation in a high-content screening assay. Clin Lab Med (2007) 0.83
Managing the health effects of climate change: Lancet and University College London Institute for Global Health Commission. Lancet (2009) 12.03
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol (2008) 4.41
Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes (2008) 4.05
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab (2008) 2.21
Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci U S A (2006) 1.88
Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun (2005) 1.76
An instrument to assess the obesogenic environment of child care centers. Am J Health Behav (2007) 1.74
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia (2010) 1.70
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res (2011) 1.63
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res (2010) 1.50
p53 negatively regulates expression of FoxM1. Cell Cycle (2009) 1.49
Chronic exposure to arsenic in the drinking water alters the expression of immune response genes in mouse lung. Environ Health Perspect (2009) 1.48
Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res (2007) 1.47
Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci (2008) 1.42
Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci (2003) 1.35
Laboratory diet profoundly alters gene expression and confounds genomic analysis in mouse liver and lung. Chem Biol Interact (2008) 1.34
Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett (2008) 1.31
Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. Circulation (2012) 1.31
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem (2010) 1.30
Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem (2010) 1.28
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer (2007) 1.20
JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res (2013) 1.19
Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration. Toxicol Sci (2005) 1.19
Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia (2011) 1.19
Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis (2013) 1.18
Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett (2007) 1.18
Early identification of HIV: empirical support for jail-based screening. PLoS One (2012) 1.15
Structural basis for substrate specificity of Escherichia coli purine nucleoside phosphorylase. J Biol Chem (2003) 1.14
ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB. Cell Rep (2013) 1.14
Exposure to arsenic at levels found inU.S. drinking water modifies expression in the mouse lung. Toxicol Sci (2007) 1.13
STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells. Biochem Biophys Res Commun (2011) 1.13
Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One (2013) 1.11
Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res (2012) 1.11
Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene (2004) 1.10
Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer (2009) 1.10
Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol (2013) 1.09
LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. J Biol Chem (2005) 1.09
Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. Bioorg Med Chem (2003) 1.09
Expression of p14ARF overcomes tumor resistance to p53. Cancer Res (2002) 1.06
Influenza vaccination coverage among pregnant women--United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep (2014) 1.06
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer (2010) 1.05
Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol (2007) 1.05
Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett (2012) 1.05
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry (2003) 1.05
Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer (2008) 1.04
Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther (2009) 1.04
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs (2011) 1.03
Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors. J Pharmacol Exp Ther (2010) 1.03
The serine-rich domain from Crk-associated substrate (p130cas) is a four-helix bundle. J Biol Chem (2005) 1.03
alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J Biol Chem (2006) 1.03
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol (2011) 1.02
Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorg Med Chem Lett (2005) 1.02
Stat3 modulates heat shock 27kDa protein expression in breast epithelial cells. Biochem Biophys Res Commun (2004) 1.02
STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer (2008) 1.01
New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci (2009) 1.01
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila) (2011) 1.01